Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALAN JOSEPH RODNEY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1881615243
CMS profile
130865
Location
WEBSTER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$117,791.12

152 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALAN JOSEPH RODNEY

NPI 1881615243 · CMS profile ID 130865

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WEBSTER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881615243?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALAN JOSEPH RODNEY, NPI 1881615243, CMS profile ID 130865. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881615243?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ALAN JOSEPH RODNEY, NPI 1881615243, CMS profile ID 130865. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881615243?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ALAN JOSEPH RODNEY, NPI 1881615243, CMS profile ID 130865, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881615243?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

152 matching records · $117,791.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 152 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 152.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $124.4008/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672748227 CMS
EISAI INC. $114.8608/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697048739 CMS
AstraZeneca Pharmaceuticals LP $125.0008/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685892861 CMS
Takeda Pharmaceuticals U.S.A., Inc. $545.0508/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376939 CMS
Takeda Pharmaceuticals U.S.A., Inc. $584.4608/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697377167 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6,600.0007/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697377159 CMS
Takeda Pharmaceuticals U.S.A., Inc. $221.7607/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697377165 CMS
Takeda Pharmaceuticals U.S.A., Inc. $75.0007/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697377169 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,620.0007/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376915 CMS
Takeda Pharmaceuticals U.S.A., Inc. $125.0007/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697377149 CMS
Takeda Pharmaceuticals U.S.A., Inc. $407.9507/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376935 CMS
Incyte Corporation $100.0007/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666275026 CMS
Incyte Corporation $500.0007/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666275169 CMS
Takeda Pharmaceuticals U.S.A., Inc. $369.5507/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376533 CMS
Takeda Pharmaceuticals U.S.A., Inc. $381.4707/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376529 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.3706/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697394395 CMS
Genentech USA, Inc. $14.6206/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681178419 CMS
Takeda Pharmaceuticals U.S.A., Inc. $51.1406/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376527 CMS
Takeda Pharmaceuticals U.S.A., Inc. $182.9406/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376535 CMS
E.R. Squibb & Sons, L.L.C. $97.0906/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651229409 CMS
Takeda Pharmaceuticals U.S.A., Inc. $262.9605/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376523 CMS
E.R. Squibb & Sons, L.L.C. $250.0005/30/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651229485 CMS
Lilly USA, LLC $7.1205/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657654667 CMS
Lilly USA, LLC $15.1405/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657654669 CMS
Lilly USA, LLC $89.0605/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657657113 CMS
Exelixis Inc. $125.0005/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686550845 CMS
Amgen Inc. $89.8905/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662154925 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.2405/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697394335 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.1605/07/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700321619 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6,600.0005/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376869 CMS
Takeda Pharmaceuticals U.S.A., Inc. $116.2505/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697380969 CMS
Genentech USA, Inc. $16.6204/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681284217 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.1604/16/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700321621 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,189.1304/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697407503 CMS
Seattle Genetics, Inc. $125.0003/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678802135 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,620.0003/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697373269 CMS
Takeda Pharmaceuticals U.S.A., Inc. $80.5403/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697381149 CMS
Takeda Pharmaceuticals U.S.A., Inc. $217.3503/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697373273 CMS
Genentech USA, Inc. $80.5003/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681315357 CMS
SANOFI-AVENTIS U.S. LLC $74.9903/19/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693937773 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.1603/04/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700321617 CMS
Seattle Genetics, Inc. $1,500.0003/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678802141 CMS
Seattle Genetics, Inc. $18.5603/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678802143 CMS
Seattle Genetics, Inc. $18.0003/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678802145 CMS
Seattle Genetics, Inc. $45.2103/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678802147 CMS
E.R. Squibb & Sons, L.L.C. $47.6703/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651229339 CMS
E.R. Squibb & Sons, L.L.C. $97.5903/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651229373 CMS
Takeda Pharmaceuticals U.S.A., Inc. $104.5102/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697370949 CMS
Takeda Pharmaceuticals U.S.A., Inc. $97.6702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697380395 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,300.0002/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697407141 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $117,791.12 152
PY2020 $29,474.86 42
PY2021 $16,256.59 25
PY2022 $91,923.55 184
PY2023 $68,862.16 159
PY2024 $80,071.55 178
PY2025 $41,115.50 150

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $102,650.00 16
PY2024 Principal investigator $29,913.84 22
PY2023 Principal investigator $7,519.20 8
PY2022 Principal investigator $26,855.52 11
PY2021 Principal investigator $18,098.52 52
PY2020 Principal investigator $14,998.52 25
PY2019 Principal investigator $11,155.52 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

16 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327116
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327251
Principal investigator 1 Janssen Research & Development, LLC $17,000.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327879
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328429
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328778
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329594
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329728
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175326786
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,250.00 11/12/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer No dispute reported 06/30/2026 1185542586
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,750.00 11/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185542588
Principal investigator 1 TOLMAR, INC. $1,200.00 10/29/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH, LLC
TOL2506A No dispute reported 06/30/2026 1237321230
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,050.00 07/31/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185542584
Principal investigator 1 TOLMAR, INC. $1,200.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH, LLC
TOL2506A No dispute reported 06/30/2026 1237321533
Principal investigator 1 AstraZeneca Pharmaceuticals LP $28,500.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185542582
Principal investigator 1 Genentech, Inc. $19,000.00 04/28/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC No dispute reported 06/30/2026 1211676363
Principal investigator 1 TOLMAR, INC. $1,200.00 04/11/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH, LLC
TOL2506A No dispute reported 06/30/2026 1237321465